**Supplementary Table S8.** Kaplan-Meier analysis using a log rank (Mantel-Cox) test to compare survival among the treatment groups represented in Figure 5. A total of 9 comparisons between groups were conducted. P-values were not adjusted for multiple comparisons.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Test** | **Group 1** | **Group 2** | **Group 1 mOS (d)** | **Group 2 mOS (d)** | **Hazard ratio** | **Chi square** | **p value** |
| 1 | Isotype mix | Anti-PD-L1 | 20 | 20 | 0.9318 | 0.2821 | 0.5954 |
| 2 | Isotype Mix | STAT3 | 20 | 28 | 0.2703 | 27.45 | < 0.0001\* |
| 3 | Isotype Mix | Anti-PD-L1 plus anti-CTLA-4 | 20 | 23.5 | 0.4360 | 11.87 | 0.0006\* |
| 4 | Isotype Mix | STAT3 plus anti-PD-L1 | 20 | 48 | 0.2381 | 30.8 | < 0.0001\* |
| 5 | Isotype Mix | STAT3 plus anti-PD-L1 and anti-CTLA-4 | 20 | NR | 0.1062 | 34.94 | < 0.0001\* |
| 6 | STAT3 | STAT3 plus anti-PD-L1 | 28 | 48 | 0.5014 | 3.947 | 0.0470\* |
| 7 | STAT3 | STAT3 plus anti-PD-L1 and anti-CTLA-4 | 28 | NR | 0.1090 | 25.40 | < 0.0001\* |
| 8 | Anti-PD-L1 | STAT3 plus anti-PD-L1 | 20 | 48 | 0.233 | 32.26 | < 0.0001\* |
| 9 | Anti-PD-L1 plus anti-CTLA-4 | STAT3 plus anti-PD-L1 and anti-CTLA-4 | 23.5 | NR | 0.1106 | 24.41 | < 0.0001\* |

\*Comparison is statistically significant.

NR, not reached (> 74 days)